» Articles » PMID: 24249434

Additive Postprandial Glucose-lowering Effects of Mitiglinide and Sitagliptin in Patients with Type 2 Diabetes Mellitus

Overview
Journal Adv Ther
Date 2013 Nov 20
PMID 24249434
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The aim of this research was to compare the pharmacodynamics of the combination of mitiglinide and sitagliptin to that of each agent alone in Korean patients with type 2 diabetes mellitus (T2DM).

Methods: Patients with T2DM received mitiglinide alone, sitagliptin alone, or both drugs together in randomized sequence. A meal tolerance test (MTT) was conducted for each group, and plasma concentrations of glucose, insulin, C-peptide, glucagon, and intact glucagon-like peptide-1, and dipeptidyl peptidase-4 activity were measured from 2 h before breakfast through 4 h after breakfast on day 0 (pretreatment) and day 1 (posttreatment) of each treatment period. Integrated values of these pharmacodynamic variables were analyzed for changes from pretreatment to posttreatment and for differences between the three treatment groups.

Results: Twenty-six patients with glycated hemoglobin A1c level of 7.4% ± 0.6%, fasting plasma glucose concentration of 141 ± 22 mg/dL, postprandial plasma glucose (PPG) concentration of 264 ± 48 mg/dL 1 h after the MTT, and diabetes duration of 3.0 ± 3.1 years (mean ± SD) were included in the study. Compared with mitiglinide or sitagliptin alone, the combination treatment lowered PPG additively (P < 0.001 vs. mitiglinide or sitagliptin alone) and the insulin secretory response (P = 0.03 vs. mitiglinide or sitagliptin alone). The integrated insulin concentrations changed significantly from before to after treatment (P < 0.01), but the change did not differ between the combination and mitiglinide groups. The insulinogenic index increased significantly after the combination treatment (P < 0.001 vs. mitiglinide or sitagliptin alone). The combination of mitiglinide and sitagliptin was generally well tolerated, with no hypoglycemic events.

Conclusions: The combination of mitiglinide and sitagliptin did not trigger hypoglycemia and controlled postprandial glucose excursion more effectively compared with either drug alone.

Citing Articles

The effects of macronutrients composition on hormones and substrates during a meal tolerance test in drugnaive and sitagliptin-treated individuals with type 2 diabetes: a randomized crossover study.

da Silva Schreiber C, Rafacho A, Silverio R, Betti R, Lerario A, Lotenberg A Arch Endocrinol Metab. 2022; 66(3):312-323.

PMID: 35551683 PMC: 9832851. DOI: 10.20945/2359-3997000000478.


Decreased glucagon levels and decreased insulin secretion after sitagliptin versus mitiglinide administration with similar glycemic levels following an oral glucose load: a randomized crossover pharmaceutical mechanistic study.

Akiyama Y, Morita-Ohkubo T, Oshitani N, Ohno Y, Aso Y, Inukai T Diabetol Int. 2019; 7(1):25-33.

PMID: 30603240 PMC: 6214467. DOI: 10.1007/s13340-015-0207-1.


Clinical utility and patient considerations in the use of the sitagliptin-metformin combination in Chinese patients.

Du Q, Wang Y, Yang S, Han P Patient Prefer Adherence. 2015; 9:281-7.

PMID: 25709414 PMC: 4332288. DOI: 10.2147/PPA.S64691.